SARS-CoV2 --Lab Origin-- The final word, and PROOF beyond reasonable doubt.

What I am about to describe has already been published in the peer-reviewed journal "Frontiers in Virology" [link to www.frontiersin.org (secure)]

In DNA, "C-G" and "T-A" are the two types of bonds made.
Consider the bold sequence of 19 nucleotides from SARS-COV-2 below..

CTCCTCGGCGGGCACGTAG
GAGGAGCCGCCCGTGCATC

I have listed the "complement" sequence directly below the bold sequence, to make it clear going forward what I mean.
(The complement is what would appear in the double-stranded DNA corresponding to the RNA of SARS-COV-2.)


Consider, there are FOUR possibilities (C,T,A,G) for each of the 19 positions above.
Using basic probability, 4-to-the-power-19 i.e. 4x4x4x4x4....
Gives a 1-in-274,877,906,944 chance.
(I'm willing to double the chance for a reverse sequence!)


Now, what are the odds of this Moderna Inc patent having the exact reverse complement string of 19 nucleic acids, right on the Furin cleavage site, never before seen in any virus....
Patent office "lengthy table" for Sequence ID 11652 from Moderna Inc patent 9587003B2: [link to seqdata.uspto.gov (secure)]
(I followed the procedure at [link to www.firsthandsources.com (secure)] to get to the above patented sequence by Moderna Inc...)

In the patent table, search for CTACGTGC
You will see a longer sequence, with spaces:
"ctacgtgc ccgccgagga g"

Reverse it, noting that reverse transcription is how RNA is made into DNA...
gaggagccgcccgtgcatc
Compare to the beginning of this post.."complement sequence".


Now, you wanna tell me again how it's a natural source?


==================================

[link to www.frontiersin.org (secure)]
Journal: Frontiers in Virology., 21 February 2022
"The absence of CTCCTCGGCGGGCACGTAG from eukaryotic or viral genome in the BLAST database makes recombination in an intermediate host an unlikely explanation for its presence in SARS-CoV-2."

"While numerous point mutation differences exist between SARS-CoV-2 and RaTG13, only one insertion and dissimilarity exceeding 3 nucleotides (nt): a 12-nucleotide insertion coding for four amino acids (aa 681-684, PRRA) in the SARS-CoV-2 S protein has been discovered."

"A BLAST search for the 12-nucleotide insertion led us to a 100% reverse match in a proprietary sequence (SEQ ID11652, nt 2751-2733) found in the US patent 9,587,003 filed on Feb. 4, 2016 (10) (Figure 1)."

"Examination of SEQ ID11652 revealed that the match extends beyond the 12-nucleotide insertion to a 19-nucleotide sequence: 5'-CTACGTGCCCGCCGAGGAG-3'; (nt 2733-2751 of SEQ ID11652)"